目的：探讨卡波姆眼用凝胶联合聚乙二醇滴眼液治疗干眼症的临床疗效。

方法：干眼症患者120例240眼随机分为观察组(60例120眼)和对照组(60例120眼)，两组患者均给予聚乙二醇滴眼液，观察组在此基础上使用卡波姆眼用凝胶，疗程为1mo。对两组患者白细胞介素-1β(interleukin-1β，IL-1β)水平和肿瘤坏死因子-α(tumor necrosis factor-α，TNF-α)水平、眼部症状评分\〖眼表疾病指数(ocular surface disease index，OSDI)、泪膜破裂时间(break-up time，BUT)、基础泪液分泌试验Ⅰ(Schirmer Ⅰ test，SⅠt)、角膜荧光素染色(corneal fluorescein staining，FL)\〗、疗效和不良反应进行比较。

结果：治疗后两组患者泪液中IL-1β和TNF-α水平、OSDI和FL较治疗前均明显降低，BUT和SⅠt较治疗前均明显升高，差异均具有统计学意义(P<0.05)，且观察组泪液中IL-1β水平、TNF-α 水平、OSDI、BUT、SⅠt、FL改善程度均优于对照组(P<0.05)。对照组总有效率明显低于观察组，差异具有统计学意义(χ²=5.065，P=0.024)。两组患者中无1例出现眼部不适症状和药物不耐受。

结论：卡波姆眼用凝胶联合聚乙二醇滴眼液治疗干眼症疗效明显，优于单用聚乙二醇滴眼液，且不增加患者的不良反应。

METHODS: Totally 120 dry eye patients(240 eyes)were randomly divided into the observation group(n=60 cases)and the control group(n=60 cases). Two groups were given the polyethylene glycol eye drops. On the basis of this, the observation group were given the carbomer eye gel. The course of treatment was 1mo. The levels of IL-1β and TNF-α, eye symptom score \〖ocular surface disease index(OSDI), break-up time(BUT), Schirmer Ⅰ test(SⅠt), corneal fluorescein staining(FL)\〗, efficacy and adverse reactions in two groups were compared.

RESULTS: After treatment, the levels of IL-1β and TNF-α, OSDI and FL in two groups were significantly lower than those before treatment and BUT and SⅠT were significantly higher than those before treatment, showing statistically significant differences(P<0.05). Moreover, the levels of IL-1β and TNF-α, OSDI, BUT, SⅠT, FL in the observation group were improved better than those in the control group(P<0.05). The total effective rate of the control group was significantly lower than that of the observation group, indicating statistically significant difference(χ²=5.065, P=0.024). There were no ocular symptoms and drug intolerance in two groups.

CONCLUSION: Carbomer eye gel combined with polyethylene glycol eye drops has obvious curative effect on dry eye, which is better than that treated by polyethylene glycol eye drops, and this combination does not increase the adverse reactions.